--- title: "Alnylam Pharmaceuticals (ALNY) news: lawsuit" url: "https://aibio.space/companies/alnylam-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "ALNY lawsuit news. Alnylam Pharmaceuticals news for investors: Alnylam develops and sells RNA interference (RNAi) drugs that silence disease-causing genes…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Alnylam's Amvuttra launch slows as the RNAi pipeline reaches for bigger diseases Alnylam is a profitable RNAi company that depends on Amvuttra in ATTR cardiomyopathy. The July guidance cut signals slower growth ahead, while the larger pipeline bets in hypertension and Alzheimer's will take years to read out. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view A profitable RNAi company with six approved medicines, but the July TTR guidance cut signals slower Amvuttra growth and the larger pipeline bets read out late. - **Technology**: 2/2 - **Odds**: 1/2 - **Balance sheet**: 2/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Validated RNAi platform.** Six approved medicines, and Amvuttra cut death and cardiovascular events 28.2% in HELIOS-B. - **Odds**: **Good in TTR, open elsewhere.** Nucresiran hits a proven target, while zilebesiran and mivelsiran face long, uncertain trials. - **Balance sheet**: **Self-funding now.** Alnylam earned $164.5 million in Q2 GAAP net income and held $3.3 billion at June 30. - **Main risk**: **Slowing ATTR-CM growth.** TTR guidance was cut by $200 million at both ends after second-line US demand moderated. - **Watch next**: **Third-quarter results.** Alnylam reports on October 29, after Huntington's data at EHDN on October 23. ## Top news on Alnylam 1. 2026-10-29 Legal [Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open. ## Dates **October 23, 2026** Phase 1 ALN-HTT02 Huntington's data at EHDN [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) **October 29, 2026** Third-quarter 2026 results, before US markets open [Source](https://investors.alnylam.com/press-release?id=2677181f-428b-435c-b33c-cc47191b7c6f) **November 2026** FDA target action date for partner Regeneron's cemdisiran [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) **2H 2026** Clinical data for ALN-6400 and the obesity drug ALN-2232 [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) **2028** Initial results from phase 2 cAPPricorn-1 in cerebral amyloid angiopathy [Source](https://investors.alnylam.com/press-release?id=c5e84aa4-7332-43b4-a4ff-ba9a305d434f) ## The money $3.3 billion in cash, cash equivalents and marketable securities at June 30, 2026 (Q2 2026). The company was profitable on a GAAP basis in the quarter and gave no runway guidance. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) Q2 2026 total revenue $1.29 billion, up 67%; net product revenue $1.17 billion, including Amvuttra $1.01 billion. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) ## Risks on the record - Alnylam cut 2026 TTR revenue guidance to $4.2 billion to $4.5 billion after second-line US ATTR-CM demand moderated. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) - Amvuttra made $1.01 billion of $1.17 billion in Q2 2026 net product revenue, so the business depends on one drug. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) - The company depends on partners including Roche, Novartis, Sanofi and Regeneron for some development and commercialization. [Source](https://investors.alnylam.com/press-release?id=03e652db-b6dc-4793-89e1-043d1b8eee54) ## Questions investors ask ### What is aibio.space's Investor Rank for Alnylam Pharmaceuticals? 7 out of 10, our positive view. A profitable RNAi company with six approved medicines, but the July TTR guidance cut signals slower Amvuttra growth and the larger pipeline bets read out late. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### When does Alnylam report third quarter 2026 earnings? Alnylam will report third-quarter 2026 results on Thursday, October 29, 2026, before US markets open. A conference call follows at 8:30 am ET. [Source](https://investors.alnylam.com/press-release?id=2677181f-428b-435c-b33c-cc47191b7c6f) ### Why did Alnylam lower its 2026 guidance? Alnylam cut its TTR revenue guidance to $4.2 billion to $4.5 billion from $4.4 billion to $4.7 billion. It cited moderating second-line US demand for Amvuttra in ATTR-CM after early pent-up demand. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) ### How much were Amvuttra sales in Q2 2026? Amvuttra net product revenue was $1.01 billion in the second quarter of 2026, up 106% from a year earlier. Total Alnylam revenue was $1.29 billion. [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) ### What is the Alnylam and Inceptive AI deal? Alnylam will use Inceptive's generative AI models to design siRNA drugs. The deal is worth up to $2 billion, with $30 million upfront in cash and equity and the rest tied to milestones. [Source](https://investors.alnylam.com/press-release?id=12c82628-531a-443b-b21b-26cc5b51230b) ### Does Amvuttra work in ATTR-CM patients already taking tafamidis? A prespecified HELIOS-B subgroup analysis found a consistent effect on death and recurrent cardiovascular events with or without baseline tafamidis. The trial was not powered to prove benefit in the tafamidis group, and the quality-of-life effect was smaller there. [Source](https://investors.alnylam.com/press-release?id=9c44884f-61bb-4f2e-85d5-09f4659cfc7c) ### What is the latest Alnylam Pharmaceuticals (ALNY) stock news? Our latest story on Alnylam Pharmaceuticals, dated Oct 29, 2026: "Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena". Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open. [Source](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) ### Is Alnylam Pharmaceuticals facing a lawsuit? Our latest legal story, dated Oct 29, 2026: "Alnylam details Texas patent suit, two Cipla patent cases and a U.S. Attorney subpoena". Alnylam's 10-Q for the quarter ended September 30, 2026 says the University of Texas System's patent suit over Onpattro now sits in Massachusetts, with trial set for August 2027. Alnylam is the plaintiff in two patent suits against Cipla, and a U.S. Attorney's Office subpoena on pricing records is open. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/alnylam-details-texas-patent-suit-two-cipla-patent-cases-u-s-attorney/) ### What is Alnylam Pharmaceuticals's market cap? We do not publish live share prices. In its annual report, Alnylam Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $42.63 billion as of Jun 30, 2025. Source ### Is Alnylam Pharmaceuticals a smaller reporting company? SEC records list Alnylam Pharmaceuticals, Inc.'s filer category as: Large accelerated filer. Source ### Where is Alnylam Pharmaceuticals headquartered? SEC records list its business address as 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142. Source ### When does Alnylam Pharmaceuticals's fiscal year end? Alnylam Pharmaceuticals, Inc.'s fiscal year ends on December 31, per SEC records. Source ### What did Alnylam Pharmaceuticals last file with the SEC? Its most recent filing in our record is a 10-Q filed 2026-07-30. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) ### What was Alnylam Pharmaceuticals called before? SEC records list these former names: ALNYLAM PHARMACEUTICALS INC. Source ### What industry is Alnylam Pharmaceuticals in? Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source ## Legal and investor matters Checked against Alnylam Pharmaceuticals filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. Alnylam's 10-Q filed 2026-07-30 (Part II, Item 1) refers to Note 12, Commitments and Contingencies, for its material pending legal proceedings. That note describes patent litigation and a U.S. Attorney's Office subpoena. [Source](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) 1. 2026-03-13 Litigation Alnylam and Novartis sue Cipla over generic Leqvio application On 2026-03-13 Alnylam and its collaborators Novartis Pharmaceuticals, Novartis Technology and The Medicines Company sued Cipla USA and Cipla Ltd in the U.S. District Court for the District of Delaware. The patent infringement suit is based on Cipla's abbreviated new drug application seeking FDA approval to market a generic version of Leqvio (inclisiran). The 10-Q filed 2026-07-30 reports no ruling. U.S. District Court for the District of Delaware · Status: filed [Alnylam Form 10-Q (2026-07-30)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) 2. 2025-12-15 Litigation Texas patent suit over Onpattro transferred to Massachusetts The Board of Regents of the University of Texas System sued Alnylam on 2024-12-12 in the Western District of Texas, alleging that making, using and commercializing ONPATTRO infringes U.S. Patent No. 8,895,717. On 2025-12-15 the court found venue improper and ordered the case transferred to the District of Massachusetts. A claim construction hearing was held in July 2026. The 10-Q filed 2026-07-30 reports no material loss contingencies accrued and describes no ruling on infringement. U.S. District Court for the District of Massachusetts (transferred from the Western District of Texas) · Status: pending [Alnylam Form 10-Q (2026-07-30)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) 3. 2025-12-10 Financing Alnylam repurchases $34.4 million of 2027 convertible notes On 2025-12-10 Alnylam agreed in privately negotiated transactions to repurchase about $34.4 million principal amount of its 1.00% convertible senior notes due 2027 for about $51.9 million including accrued interest. Part of the price depends on the volume-weighted average share price from 2025-12-11. After closing, about $362.8 million principal amount of the notes was expected to remain outstanding. [Alnylam Form 8-K](https://www.sec.gov/Archives/edgar/data/1178670/000119312525315047/d201569d8k.htm) 4. 2025-10-30 Regulatory Alnylam receives U.S. Attorney subpoena on government price reporting Alnylam disclosed in its 10-Q filed 2025-10-30 that in October 2025 it received a subpoena from the U.S. Attorney's Office for the District of Massachusetts. The subpoena seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI, including certain fee and discount arrangements with distributors. The 10-Q filed 2026-07-30 says Alnylam has produced responsive records and continues to engage with the office. U.S. Attorney's Office for the District of Massachusetts · Status: pending [Alnylam Form 10-Q (2026-07-30)](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) 5. 2025-10-30 Litigation Alnylam settles mRNA vaccine patent suits with Moderna and Pfizer Alnylam sued Moderna and Pfizer in the District of Delaware in March 2022 over their mRNA COVID-19 vaccines, and Pfizer later added BioNTech. According to the 10-Q filed 2025-10-30, Alnylam settled all claims with Moderna in August 2025 and with Pfizer in September 2025. The 10-Q does not give settlement terms. A related Acuitas declaratory judgment action was dismissed without prejudice on 2025-07-01. U.S. District Court for the District of Delaware · Status: settled [Alnylam Form 10-Q (2025-10-30)](https://www.sec.gov/Archives/edgar/data/1178670/000162828025047345/alny-20250930.htm) 6. 2025-09-30 Financing Alnylam enters $500 million revolving credit facility On 2025-09-30 Alnylam entered a credit agreement with Bank of America as administrative agent that provides a $500.0 million revolving line of credit, including a $150.0 million letter of credit sublimit. Alnylam may add incremental revolving commitments or term loans, but the lenders are not obliged to provide them. Proceeds may be used for working capital and general corporate purposes. [Alnylam Form 8-K](https://www.sec.gov/Archives/edgar/data/1178670/000119312525230201/d19737d8k.htm) 7. 2025-09-12 Financing Alnylam completes $661.25 million convertible notes offering On 2025-09-12 Alnylam completed an offering of 0.00% convertible senior notes due 2028. The initial $575.0 million was increased by $86.25 million when the initial purchasers exercised their option on 2025-09-10, for a total of $661.25 million. The notes mature on 2028-09-15 unless earlier converted, redeemed or repurchased. Alnylam used about $35.3 million of net proceeds for capped call transactions. [Alnylam Form 8-K](https://www.sec.gov/Archives/edgar/data/1178670/000119312525202366/d949176d8k.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Nucresiran | ATTR amyloidosis with cardiomyopathy (and polyneuropathy) | Phase 3 (TRITON-CM, TRITON-PN) [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) | | Zilebesiran (with Roche) | Hypertension with high cardiovascular risk | Phase 3 outcomes trial (ZENITH) [Source](https://investors.alnylam.com/press-release?id=6dfa6e89-b58c-4e9d-803b-3a9e26e85b5d) | | Mivelsiran | Cerebral amyloid angiopathy; Down syndrome-associated Alzheimer's | Phase 2 [Source](https://investors.alnylam.com/press-release?id=c5e84aa4-7332-43b4-a4ff-ba9a305d434f) | | ALN-6400 | Bleeding disorders | Phase 2 [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) | | ALN-HTT02 | Huntington's disease | Phase 1, data due October 23, 2026 [Source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) | Opinion · Devil's advocate ## Fact-check-o-meter Some gaps Open about the guidance cut, but the August data release leans on subgroups and post hoc work Alnylam's quarterly release is direct that it lowered TTR guidance because second-line demand normalized, and its numbers match the 10-Q. The August ESC release is more generous to its data: it features a post hoc zilebesiran subgroup that the 10-Q does not describe as a win, and it presents a prespecified HELIOS-B subgroup as consistent benefit while stating that the trial was not powered for that population. The 10-Q also discloses a U.S. Attorney subpoena that the releases do not mention. 1. Press release vs filing · weight medium Guidance cut explained as demand normalization; competition sits in risk factors **The company said:** "the normalization of growth in second line volume after satisfying pent-up demand from patients waiting for a new therapy" [source](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) **The record says:** The 10-Q does not repeat that explanation. Its risk factors state that "AMVUTTRA is administered through a subcutaneous injection and may not compete favorably with other available options for the treatment of ATTR-CM, including VYNDAQEL/VYNDAMAX, which is marketed by Pfizer" and name an oral competitor from BridgeBio. The release's own revenue detail says U.S. TTR growth of $106 million versus Q1 combined a $129 million demand increase with about $20 million of inventory impact and "a modest reduction in net price." [source](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) **Our view:** The release is candid that guidance fell, and the cause it gives is plausible. The filing keeps competition and pricing as open risks without tying them to the cut, so investors cannot tell from either document how much of the slowdown is one-time pent-up demand versus share. 2. Science · weight medium HELIOS-B tafamidis subgroup: consistent direction, not powered, weaker quality-of-life effect **The company said:** "The treatment effect for vutrisiran on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events through 33-36 months was consistent irrespective of baseline tafamidis use" [source](https://investors.alnylam.com/press-release?id=9c44884f-61bb-4f2e-85d5-09f4659cfc7c) **The record says:** ClinicalTrials.gov lists HELIOS-B as randomized, quadruple masked, 655 participants, with the primary composite assessed up to month 36 in the overall population and, as a second primary outcome, in the vutrisiran monotherapy subgroup. The release itself adds that "HELIOS-B was not powered to establish the benefit of vutrisiran specifically in the population of patients receiving background tafamidis at baseline" (259 of 654 patients) and that the Kansas City Cardiomyopathy Questionnaire improvement showed "an attenuated effect seen among patients receiving tafamidis at baseline." It labels the intrinsic capacity and adverse-event analyses "post hoc". [source](https://clinicaltrials.gov/study/NCT04153149) **Our view:** The release calls the tafamidis analysis prespecified and discloses the limits, which is to its credit, but the headline and quote lead with consistency. For a market where many patients already take tafamidis, the combination question is commercially central and is not answered by this trial. 3. Science · weight medium Zilebesiran: post hoc subgroup featured; the 10-Q describes KARDIA-3 as informing design **The company said:** "In patients who were receiving a background diuretic with an office systolic BP (SBP) ≥140 mmHg at baseline, zilebesiran achieved greater reductions in mean office and 24-hour ambulatory SBP than in the overall study population." [source](https://investors.alnylam.com/press-release?id=9c44884f-61bb-4f2e-85d5-09f4659cfc7c) **The record says:** The release's safety sentence refers to "this post hoc subgroup". ClinicalTrials.gov lists KARDIA-3 as a 375-participant randomized, quadruple masked phase 2 with a single primary outcome, change from baseline at Month 3 in mean seated office systolic blood pressure. The 10-Q says only that KARDIA-3 "met the objective of informing the design, patient population, and dose for a global Phase 3 cardiovascular outcomes trial." [source](https://clinicaltrials.gov/study/NCT06272487) **Our view:** Choosing a diuretic subgroup after seeing results is how phase 3 designs are shaped, but it is not evidence the effect will hold in ZENITH. The 10-Q wording describes the study's role in shaping the phase 3 design and does not report an efficacy result. 4. Legal and disclosure record · weight medium U.S. Attorney subpoena on price reporting; two patent suits; no securities case listed **The record says:** Note 12 of the Q2 2026 10-Q states: "In October 2025, we received a subpoena from the U.S. Attorney's Office for the District of Massachusetts seeking documents pertaining to our government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI", and that Alnylam has produced records and is "continuing to engage with the U.S. Attorney's Office." It also lists a patent suit by the Board of Regents of the University of Texas System over ONPATTRO, filed December 12, 2024 and now in the U.S. District Court for the District of Massachusetts with a claim construction hearing held in July 2026, and a March 13, 2026 suit by Alnylam and Novartis against Cipla in the District of Delaware over a generic Leqvio application. The 10-Q says "There were no material loss contingencies accrued as of June 30, 2026 or December 31, 2025." No securities class action is listed in Note 12. [source](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) **Our view:** A subpoena is an information request, not a finding, and the filing reports no charges. It covers all four marketed products, though, and the Q2 release does not mention it. Documents we compared - [Alnylam Q2 2026 financial results press release](https://investors.alnylam.com/press-release?id=ddc78e15-7847-4066-8fdb-3562023a60f4) 2026-07-30 - [Alnylam Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) 2026-07-30 - [Alnylam press release: new data at ESC Congress 2026](https://investors.alnylam.com/press-release?id=9c44884f-61bb-4f2e-85d5-09f4659cfc7c) 2026-08-30 - [ClinicalTrials.gov NCT04153149 (HELIOS-B)](https://clinicaltrials.gov/study/NCT04153149) 2026-01-12 - [ClinicalTrials.gov NCT06272487 (KARDIA-3)](https://clinicaltrials.gov/study/NCT06272487) 2026-03-02 This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALNY on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALNY/). ## SEC filings and registration - **SEC name**: Alnylam Pharmaceuticals, Inc. - **CIK**: 1178670 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: ALNY (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 675 WEST KENDALL STREET, CAMBRIDGE, MA, 02142 - **Phone**: (617) 551-8200 - **Shares outstanding**: 133,809,118 as of 2026-07-24 (10-Q filed 2026-07-30) - **Former names**: ALNYLAM PHARMACEUTICALS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000062/alny-20260630.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1178670/000117867026000060/alny-20260730.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm) filed 2026-05-27 - [10-Q](https://www.sec.gov/Archives/edgar/data/1178670/000162828026028605/alny-20260331.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026028601/alny-20260430.htm) filed 2026-04-30 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1178670/000162828026023923/alny-20260406.htm) filed 2026-04-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026014728/alny-20260302.htm) filed 2026-03-04 - [10-K](https://www.sec.gov/Archives/edgar/data/1178670/000162828026007497/alny-20251231.htm) filed 2026-02-12 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001178670), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/alnylam-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alnylam Pharmaceuticals (ALNY) news: lawsuit", 2026-10-31, https://aibio.space/companies/alnylam-pharmaceuticals/